Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.

Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol. 2010 Jul; 5(7):1312-29.

View in: PubMed

subject areas

Animals
Disease Models, Animal
Hamartoma
Humans
Intracellular Signaling Peptides and Proteins
Polycystic Kidney Diseases
Protein Kinase Inhibitors
Risk Assessment
Signal Transduction
TOR Serine-Threonine Kinases
Treatment Outcome

authors with profiles

Arlene Chapman